메뉴 건너뛰기




Volumn 38, Issue 4, 2010, Pages 554-565

Disposition and metabolism of semagacestat, a γ-secretase inhibitor, in humans

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; GAMMA SECRETASE INHIBITOR; SEMAGACESTAT;

EID: 77950196208     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030841     Document Type: Article
Times cited : (24)

References (27)
  • 2
    • 36148961146 scopus 로고    scopus 로고
    • The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates
    • Burk O and Schwab M (2007) The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates. Eur J Clin Pharmacol 63:1097-1098.
    • (2007) Eur J Clin Pharmacol , vol.63 , pp. 1097-1098
    • Burk, O.1    Schwab, M.2
  • 4
    • 34247371529 scopus 로고    scopus 로고
    • Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes
    • Dennison JB, Jones DR, Renbarger JL, and Hall SD (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321:553-563.
    • (2007) J Pharmacol Exp Ther , vol.321 , pp. 553-563
    • Dennison, J.B.1    Jones, D.R.2    Renbarger, J.L.3    Hall, S.D.4
  • 5
    • 21044454884 scopus 로고    scopus 로고
    • Diagnosis and treatment of Alzheimer's disease
    • Desai AK and Grossberg GT (2005) Diagnosis and treatment of Alzheimer's disease. Neurology 64:S34-S39.
    • (2005) Neurology , vol.64
    • Desai, A.K.1    Grossberg, G.T.2
  • 8
    • 21544438539 scopus 로고    scopus 로고
    • Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor
    • Gitter B, Czilli D, Li W, Dieckman D, Bender M, Nissen J, Mabry T, Yin T, Boggs L, McClure D, et al. (2004) Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor. Neurobiol Aging 25 (Suppl 2):S571.
    • (2004) Neurobiol Aging , vol.25 , Issue.SUPPL. 2
    • Gitter, B.1    Czilli, D.2    Li, W.3    Dieckman, D.4    Bender, M.5    Nissen, J.6    Mabry, T.7    Yin, T.8    Boggs, L.9    McClure, D.10
  • 9
    • 21544470736 scopus 로고    scopus 로고
    • Reduction in Aβ(1- 40) and Aβ(1-42) in CSF and plasma in the beagle dog following acute oral dosing of the γ secretase inhibitor, LY450139
    • Hyslop P, May P, Audia J, Calligaro D, McMillian C, Garner C, Cramer J, Gitter B, Porter W, and Nissen J (2004) Reduction in Aβ(1- 40) and Aβ(1-42) in CSF and plasma in the beagle dog following acute oral dosing of the γ secretase inhibitor, LY450139. Neurobiol Aging 25 (Suppl 2):S147.
    • (2004) Neurobiol Aging , vol.25 , Issue.SUPPL. 2
    • Hyslop, P.1    May, P.2    Audia, J.3    Calligaro, D.4    McMillian, C.5    Garner, C.6    Cramer, J.7    Gitter, B.8    Porter, W.9    Nissen, J.10
  • 10
    • 40349111175 scopus 로고    scopus 로고
    • Therapeutic potential of γ-secretase inhibitors and modulators
    • Imbimbo BP (2008) Therapeutic potential of γ-secretase inhibitors and modulators. Curr Top Med Chem 8:54-61.
    • (2008) Curr Top Med Chem , vol.8 , pp. 54-61
    • Imbimbo, B.P.1
  • 15
    • 21544457270 scopus 로고    scopus 로고
    • Multi-compartmental pharmacodynamic assessment of the functional γ-secretase inhibitor LY450139 in PDAPP transgenic and nontransgenic mice
    • (Suppl 2)
    • May P, Yang Z, Li W-Y, Hyslop P, Siemers E, and Boggs L (2004) Multi-compartmental pharmacodynamic assessment of the functional γ-secretase inhibitor LY450139 in PDAPP transgenic and nontransgenic mice. Neurobiol Aging 25 (Suppl 2):S65.
    • (2004) Neurobiol Aging , vol.25
    • May, P.1    Yang, Z.2    Li, W.-Y.3    Hyslop, P.4    Siemers, E.5    Boggs, L.6
  • 16
    • 21544432780 scopus 로고    scopus 로고
    • Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months
    • Ness D, Boggs L, Hepburn DL, Gitter B, Long G, May P, Piroozi K, Schafer K, and Yang Z (2004) Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiol Aging 25 (Suppl 2):S238-S239.
    • (2004) Neurobiol Aging , vol.25 , Issue.SUPPL. 2
    • Ness, D.1    Boggs, L.2    Hepburn, D.L.3    Gitter, B.4    Long, G.5    May, P.6    Piroozi, K.7    Schafer, K.8    Yang, Z.9
  • 17
    • 40349100482 scopus 로고    scopus 로고
    • Recent progress in the medicinal chemistry of γ-secretase inhibitors
    • Olson RE and Albright CF (2008) Recent progress in the medicinal chemistry of γ-secretase inhibitors. Curr Top Med Chem 8:17-33.
    • (2008) Curr Top Med Chem , vol.8 , pp. 17-33
    • Olson, R.E.1    Albright, C.F.2
  • 18
    • 34748899687 scopus 로고    scopus 로고
    • Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes
    • Perrett HF, Barter ZE, Jones BC, Yamazaki H, Tucker GT, and Rostami-Hodjegan A (2007) Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. Drug Metab Dispos 35:1733-1736.
    • (2007) Drug Metab Dispos , vol.35 , pp. 1733-1736
    • Perrett, H.F.1    Barter, Z.E.2    Jones, B.C.3    Yamazaki, H.4    Tucker, G.T.5    Rostami-Hodjegan, A.6
  • 19
    • 0034861814 scopus 로고    scopus 로고
    • Prevalence, costs, and treatment of Alzheimer's disease and related dementia: A managed care perspective
    • Rice DP, Fillit HM, Max W, Knopman DS, Lloyd JR, and Duttagupta S (2001) Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care 7:809-818.
    • (2001) Am J Manag Care , vol.7 , pp. 809-818
    • Rice, D.P.1    Fillit, H.M.2    Max, W.3    Knopman, D.S.4    Lloyd, J.R.5    Duttagupta, S.6
  • 20
    • 0035066332 scopus 로고    scopus 로고
    • Alzheimer's disease: Genes, proteins, and therapy
    • Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
    • (2001) Physiol Rev , vol.81 , pp. 741-766
    • Selkoe, D.J.1
  • 21
    • 0028237729 scopus 로고
    • Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
    • Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
    • (1994) J Pharmacol Exp Ther , vol.270 , pp. 414-423
    • Shimada, T.1    Yamazaki, H.2    Mimura, M.3    Inui, Y.4    Guengerich, F.P.5
  • 22
    • 21544458621 scopus 로고    scopus 로고
    • Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers
    • Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, and May PC (2005) Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers. Clin Neuropharmacol 28:126-132.
    • (2005) Clin Neuropharmacol , vol.28 , pp. 126-132
    • Siemers, E.1    Skinner, M.2    Dean, R.A.3    Gonzales, C.4    Satterwhite, J.5    Farlow, M.6    Ness, D.7    May, P.C.8
  • 25
    • 0242332169 scopus 로고    scopus 로고
    • Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
    • Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, and Daly AK (2003) Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1235.
    • (2003) Transplantation , vol.76 , pp. 1233-1235
    • Thervet, E.1    Anglicheau, D.2    King, B.3    Schlageter, M.H.4    Cassinat, B.5    Beaune, P.6    Legendre, C.7    Daly, A.K.8
  • 26
    • 19144368324 scopus 로고    scopus 로고
    • Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance
    • Totah RA and Rettie AE (2005) Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77:341-352.
    • (2005) Clin Pharmacol Ther , vol.77 , pp. 341-352
    • Totah, R.A.1    Rettie, A.E.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.